BB Biotech AG

As of June 30, 2026, BB Biotech AG carries a market capitalization of 2.91B, placing it among publicly traded companies globally. Its enterprise value stands at 2.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BB Biotech AG's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, BB Biotech AG has 55.15M shares outstanding.

As of June 30, 2026, BB Biotech AG trades at a trailing price-to-earnings ratio of 3.40. The price-to-sales ratio is 3.30, and the price-to-book ratio stands at 0.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.69B versus a market cap of 2.91B, with the gap driven by net debt and cash on the balance sheet.

Over the twelve months ended June 30, 2026, BB Biotech AG posted a return on equity (ROE) of 31.86, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 31.80, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 31.86, useful for judging operating efficiency across full business cycles. The company generates approximately 11.75M in revenue per employee across its workforce of 76.15, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BB Biotech AG recorded 76,929.92 in income tax expense. That works out to an effective tax rate of 0.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 868.23M, leaving 868.15M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BB Biotech AG's stock has gained approximately 29.52% over the past 52 weeks. The 50-day moving average sits at 55.74, while the 200-day moving average is 51.85.

Over the twelve months ended June 30, 2026, BB Biotech AG generated 894.66M in revenue and converted that into 868.15M in net income, yielding earnings per share of 15.48.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BB Biotech AG paid dividends of 2.40 per share. The dividend payout ratio of 15.49 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.71, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BB Biotech AG shareholders.

BB Biotech AG's most recent stock split took place on March 29, 2016 with a 1:5 split ratio.